XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenues $ 6,599 $ 6,260 $ 12,951 $ 12,850
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,784 4,339 9,236 8,694
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,027 1,076 2,106 2,277
Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 789 844 1,610 1,878
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 6,564 6,138 12,870 12,672
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,777 4,254 9,211 8,582
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 999 1,042 2,052 2,216
Total product sales | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 788 842 1,607 1,873
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 4,626 4,228 8,816 7,935
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 3,778 3,383 7,142 6,245
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 521 562 1,049 1,112
Total HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 326 282 624 577
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 2,979 2,556 5,656 4,707
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2,439 2,095 4,600 3,801
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 302 268 606 529
Biktarvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 237 193 449 376
Complera/Eviplera        
Disaggregation of Revenue [Line Items]        
Total revenues 32 54 70 99
Complera/Eviplera | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 13 20 27 37
Complera/Eviplera | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 16 31 37 55
Complera/Eviplera | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 6 7
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 516 460 965 834
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 460 397 855 708
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 25 32 50 64
Descovy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 31 32 60 63
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 540 582 1,041 1,164
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 455 482 872 939
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 56 72 111 149
Genvoya | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 29 29 58 76
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 351 364 668 703
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 267 255 497 487
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 74 97 149 193
Odefsey | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 11 12 22 23
Stribild        
Disaggregation of Revenue [Line Items]        
Total revenues 26 33 55 66
Stribild | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 19 24 39 46
Stribild | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 8 11 16
Stribild | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 2 2 4 5
Truvada        
Disaggregation of Revenue [Line Items]        
Total revenues 42 34 74 72
Truvada | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 32 24 55 52
Truvada | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 3 5 7 9
Truvada | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 7 5 12 11
Revenue share - Symtuza        
Disaggregation of Revenue [Line Items]        
Total revenues 120 126 259 258
Revenue share - Symtuza | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 84 80 182 166
Revenue share - Symtuza | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 33 42 70 86
Revenue share - Symtuza | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 4 7 6
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 20 18 29 33
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 10 5 15 10
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 7 9 8 13
Other HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 4 6 9
Total Oncology        
Disaggregation of Revenue [Line Items]        
Total revenues 728 527 1,398 947
Total Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 462 366 893 658
Total Oncology | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 215 141 417 258
Total Oncology | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 51 21 88 32
Total Cell Therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 469 368 916 642
Total Cell Therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 272 246 542 418
Total Cell Therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 162 105 310 197
Total Cell Therapy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 34 17 65 27
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 88 73 177 136
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 56 53 114 100
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 29 20 56 35
Tecartus | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 0 6 1
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 380 295 739 506
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 217 193 427 318
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 133 85 254 162
Yescarta | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 30 17 58 26
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 260 159 482 305
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 189 120 351 240
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 53 35 107 61
Trodelvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 17 3 23 5
Total Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 711 682 1,386 1,317
Total Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 356 363 674 642
Total Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 131 124 271 247
Total Liver Disease | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 225 195 441 427
Total HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 452 448 897 847
Total HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 259 263 491 462
Total HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 95 94 209 189
Total HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 98 91 197 196
Ledipasvir/Sofosbuvir        
Disaggregation of Revenue [Line Items]        
Total revenues 15 23 30 58
Ledipasvir/Sofosbuvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 8 6 12 19
Ledipasvir/Sofosbuvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 2 4 9 8
Ledipasvir/Sofosbuvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 5 13 10 31
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 397 376 782 706
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 223 227 427 389
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 84 75 174 157
Sofosbuvir/Velpatasvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 90 74 181 159
Other HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 40 49 85 83
Other HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 28 30 51 54
Other HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 9 16 27 24
Other HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 6 5
Total HBV/HDV        
Disaggregation of Revenue [Line Items]        
Total revenues 259 234 489 470
Total HBV/HDV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 97 100 183 180
Total HBV/HDV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 35 30 62 57
Total HBV/HDV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 127 104 244 232
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 219 195 418 394
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 96 97 183 177
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 10 9 19 18
Vemlidy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 113 89 216 199
Viread        
Disaggregation of Revenue [Line Items]        
Total revenues 21 24 40 47
Viread | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 1 3 1 3
Viread | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 6 6 12 12
Viread | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 14 15 28 32
Other HBV/HBD        
Disaggregation of Revenue [Line Items]        
Total revenues 20 16 31 28
Other HBV/HBD | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Other HBV/HBD | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 20 15 31 28
Other HBV/HBD | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 256 445 829 1,980
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 97 41 349 843
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 52 126 163 430
Veklury | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 107 278 317 708
Total Other        
Disaggregation of Revenue [Line Items]        
Total revenues 243 256 442 493
Total Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 85 101 153 195
Total Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 80 88 152 169
Total Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 78 67 137 129
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 151 132 267 275
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 20 15 27 40
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 69 63 129 129
AmBisome | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 61 54 111 107
Letairis        
Disaggregation of Revenue [Line Items]        
Total revenues 39 49 70 92
Letairis | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 39 49 70 92
Letairis | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Letairis | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 53 76 105 125
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 26 37 56 63
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 10 26 22 41
Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 17 13 26 22
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 35 122 81 178
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 6 85 25 112
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 28 34 54 61
Royalty, contract and other revenues | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1 $ 2 $ 3 $ 5